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AbstrACt
Introduction Raised blood pressure (BP) is common after 
stroke and is associated with a poor prognosis, yet trials of 
BP lowering in the immediate poststroke period have not 
demonstrated a benefit. One possible explanation for this 
may be that BP variability (BPV) rather than absolute levels 
predicts outcome, as BPV is increased after stroke and 
is associated with poor outcomes. Furthermore, there is 
evidence of distinct antihypertensive class effects on BPV 
despite similar BP-lowering effects. However, whether BPV 
in the immediate poststroke period is a therapeutic target 
has not been prospectively investigated.  The objectives 
of this trial are to assess the feasibility and safety of 
recruiting patients following an acute ischaemic stroke 
or transient ischaemic attack (TIA) to an interventional 
randomised controlled trial comparing the effects of two 
different antihypertensive drug classes on BPV. Secondary 
exploratory objectives are to assess if different therapeutic 
strategies have diverse effects on levels of BPV and if this 
has an impact on outcomes.
Methods 150 adult patients with first-ever ischaemic 
stroke or TIA who require antihypertensive therapy for 
secondary prevention will be recruited within 7 days of 
the event from stroke services across three sites. After 
baseline assessments they will be randomly assigned to 
treatment with a calcium channel blocker or ACE inhibitor/
angiotensin receptor blocker-based regimen and followed 
up for a period of three months.
Ethics and dissemination Ethical and regulatory 
approvals have been granted. Dissemination is planned 
via publication in peer-reviewed medical journals and 
presentation at relevant conferences.
trial registration number ISRCTN10853487.
IntroduCtIon 
background
Raised blood pressure (BP) is common after 
acute stroke with at least 75% of patients 
having a systolic BP (SBP) >130 mm Hg at 
hospital admission1 2; SBP <130 mm Hg being 
the guideline target for secondary preven-
tion following stroke.3 Increased poststroke 
BP is associated with poor prognosis4 5 and 
may result from raised intracranial pres-
sure,6 increased sympathetic nervous system 
activity,7 abnormal baroreceptor sensitivity 
(BRS),8 haematoma expansion,9 cerebral 
oedema10 and a white-coat response.11 A spon-
taneous BP decrease usually occurs 4–10 days 
after ictus,12 but substantial BP reductions 
can be associated with cerebral hypoperfu-
sion as a consequence of poststroke dysau-
toregulation.13 We have previously reported 
that both increased 24 hours and beat-to-beat 
BP levels following acute stroke are associ-
ated with a poor prognosis.14–16 Subsequently, 
data from the International Stroke Trial 
have suggested a U-shaped relation between 
baseline SBP (within 48 hours of stroke) and 
short-term (14-day mortality) and long-term 
strengths and limitations of this study
 ► To our knowledge, this is the first prospective ran-
domised trial designed to assess the treatment of 
blood pressure variability (BPV) following acute isch-
aemic stroke/transient ischaemic attack.
 ► The protocol incorporates multiple blood  pressure 
measurement methods.
 ► The chosen therapeutic interventions are in line 
with standard clinical practice for secondary stroke 
prevention.
 ► The trial is open  label which could bias the analy-
sis of treatment effects on BPV and any impact on 
stroke outcomes, but these are secondary explor-
atory outcomes in this feasibility trial.
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(6-month death and dependency) outcomes; the lowest 
risk of death and dependency being at SBP 150 mm Hg.17 
However, there is conflicting evidence regarding acute 
stroke hypertension treatment. Data from randomised 
controlled trials (RCT) suggest that BP can be safely 
reduced after the acute stroke period, however, there 
seems to be no indication that doing so is beneficial.18–23 
Indeed, the Scandinavian Candesartan Acute Stroke 
Trial reported that it may actually be harmful, with a 
non-significant increased risk of poor 6-month functional 
outcome.23 Therefore, Cochrane meta-analysis and guide-
lines state that optimal BP management in the context of 
initial stroke management remains uncertain.3 24–26 
An alternative explanation for the lack of evidence 
that lowering elevated BP levels in acute stroke is bene-
ficial may relate to the additional effects of BP variability 
(BPV).27 Current hypertension guidelines predomi-
nantly focus on mean, usually casual, BP measurements, 
dismissing BPV as random and merely an obstacle to the 
reliable estimation of usual BP. However, on ambulatory 
or home BP monitoring, which are recommended for 
the diagnosis and management of hypertension,28 mean 
BP is found to vary substantially,29 with the extent of this 
variation associated with visit-to-visit variability in clinic 
BP.30 Indeed, there are many examples to support the 
potential importance of BPV for vascular risk.30 First, the 
predictive value of estimated usual SBP and stroke risk 
falls with age,31 yet stroke incidence rises with age and the 
relative benefit of antihypertensive therapy is maintained 
in the elderly.32 Second, an increased early-morning 
surge in BP is predictive of stroke, but is poorly associ-
ated with mean BP.33 Third, other causes of transient 
hypertension are recognised triggers of vascular events, 
including sympathetic overactivity and orthostatic hyper-
tension.34 Fourth, in the majority of studies, there is no 
threshold of baseline SBP below which vascular risk stops 
falling (though evidence for BP below 115/75 mm Hg is 
very limited),31 with antihypertensive therapy reducing 
risk even at ‘normal’ baseline SBP.35 Fifth, ‘white-coat’ 
hypertension, a common example of situational BPV, 
is associated with long-term target organ damage inde-
pendent of mean BP.36 Sixth, though hypertension is a 
recognised risk factor for vascular dementia, there is 
limited evidence of reduced dementia risk in trials of anti-
hypertensive therapy. However, a trial of calcium channel 
blockers (CCB), which have the most consistent effect 
on reducing BPV,37 38 has shown a substantial reduction 
in the incidence of dementia.39 Furthermore, in patients 
with Alzheimer’s dementia BPV is increased compared 
with matched controls, with increased BPV being inde-
pendently predictive of progressive cognitive decline in 
this patient group.40 Finally, specific group differences in 
stroke risk are not accounted for by mean BP alone, for 
example, in black individuals.41
rationale for the study
In a retrospective analysis of RCTs in a transient ischaemic 
attack (TIA) population, visit-to-visit intraindividual 
BPV was a risk factor for stroke independent of the 
mean ‘absolute’ BP level, and perhaps of greater signif-
icance.30 Additionally, within-visit systolic BPV, based 
on casual BP measurements, was correlated with visit-
to-visit systolic BPV, but was a weak predictor of future 
vascular events.30 Importantly, in a separate analysis it 
was demonstrated that BPV is reproducible and inde-
pendent of confounding factors.42 Increased BPV may 
also be an important predictor of short-term outcome 
following acute stroke. Robinson and colleagues have 
shown that beat-to-beat systolic BPV was greater in acute 
stroke compared with controls,43 and that high mean 
arterial and diastolic beat-to-beat BPV was associated with 
a worse prognosis.15 Furthermore, in a post hoc analysis 
of the Tinzaparin in Acute Ischaemic Stroke Trial, high 
systolic BPV from three to six casual BP readings, taken 
within 48 hours of symptom onset, was associated with an 
increase in death or early neurological deterioration at 
day 10.44 Conversely, a retrospective analysis of nearly 1000 
patients in the Continue or Stop Post-Stroke Antihyper-
tensives Collaborative Study and Controlling Hyperten-
sion and Hypotension Immediately Post Stroke trial did 
not demonstrate a significant association between systolic 
BPV based on two sets of three casual BP readings within 
48 hours of stroke onset and 2-week death and depen-
dency.45 Overall, a recent meta-analysis reported that 
increased systolic BPV, measured early from stroke onset, 
was associated with poor long-term functional outcome.46 
Furthermore, increased BPV may also relate to poststroke 
cognitive outcomes with evidence suggesting an associ-
ation with signs of cerebrovascular small vessel disease 
on neuroimaging,47 and deterioration in cognitive test 
scores.48 49
Clearly, there is further scope to explore the relation-
ship between BPV and outcome following acute stroke, 
in particular whether it has implications for therapeutic 
management in the immediate poststroke period. Roth-
well’s group have explored the differential effects of 
BP-lowering therapies on BPV in a hypertensive popula-
tion.37 38 Though clinical benefits with reduction in risk 
of stroke and coronary events were seen for all classes of 
antihypertensive agent, class-specific effects existed; CCBs 
reduce stroke risk to a greater extent than expected from 
mean SBP reduction alone, and beta-blockers (BB) to 
a smaller extent. A detailed analysis of the Anglo-Scan-
dinavian Cardiac Outcomes Trial-Blood Pressure 
Lowering Arm, comparing an amlodipine versus ateno-
lol-based regime, and the Medical Research Council trial, 
comparing an atenolol versus diuretic-based regime, 
reported opposite effects of CCB and BB on systolic BPV. 
In addition, this differential effect accounted for the 
disparity in observed effects on stroke risk and observed 
effects on mean SBP.38 This was confirmed in a system-
atic review and meta-analysis of 389 RCTs which also 
demonstrated that BPV is reduced by non-loop diuretic 
drugs, but increased by ACE inhibitors (ACEI) and angio-
tensin receptor blockers (ARB).37 Again, the effects on 
systolic BPV were correlated with effects on stroke risk 
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independent of differences in mean SBP.37 Prospec-
tive trials to investigate these apparent medication class 
effects on BPV would be valuable, especially comparing 
CCB and ACEI/ARB which are typically the first-line anti-
hypertensive drug classes. If, as anticipated, CCBs reduce 
BPV whereas ACEI and ARBs increase it this could be 
relevant after acute stroke, where normal cardiovascular 
autonomic and cerebrovascular autoregulatory pathways 
are impaired. BRS is important in the short-term regu-
lation of the cardiovascular system, including BP, and is 
known to be impaired following acute ischaemic stroke,8 
and associated with poor short-term and long-term prog-
nosis.50 In addition, it is well established that cerebral 
autoregulation (CA) is impaired, particularly following 
moderate to severe stroke.13 As a consequence, cerebral 
perfusion is pressure dependent, and therefore hyperten-
sive episodes related to increased BPV may contribute to 
reperfusion injuries, for example, postischaemic oedema 
and/or intracerebral haemorrhage. Conversely, hypoten-
sive episodes associated with increased BPV in the pres-
ence of impaired CA may lead to secondary ischaemia, 
particularly in the absence of a good collateral circulation.
In conclusion, increased BPV is associated with a greater 
vascular risk, independent of mean BP and may predict 
poor outcomes after stroke. Furthermore, commonly 
used antihypertensive agents have different class effects 
on BPV which may in part explain the overall differential 
effects on stroke risk for similar absolute reductions in 
mean BP in a hypertensive population. Trials to investi-
gate the potential therapeutic targeting of BPV and any 
potential benefit of doing so in acute stroke would be 
useful to address gaps in the current knowledge base.
study objectives
The primary objective of this study is to determine 
the feasibility of recruiting patients with acute stroke and 
TIA into an interventional randomised trial comparing 
the effect of different antihypertensive medication regi-
mens on BPV.
Secondary feasibility objectives are:
 ► To determine the viability of measuring changes in 
BPV from baseline to 21 (±7) days and 90 (±14) days 
by treatment arm.
 ► To assess compliance rates with BPV measurement 
methods.
 ► To assess compliance rates with the investigational 
treatments.
 ► To identify serious adverse events (SAE) associated 
with the interventions, including recurrent stroke/
TIA, other cardiovascular events, death and hospital 
readmission up to 3 months.
In addition to the feasibility objectives, exploratory 
outcomes that may be used in a future definitive RCT 
will be investigated. The proposed primary exploratory 
outcome will be modified Rankin Scale (mRS) score at 
day 90.
Exploratory secondary outcomes are:
 ► mRS at day 21.
 ► National Institutes of Health Stroke Scale (NIHSS) at 
day 21.
 ► Mean BP at day 21 and day 90.
 ► BPV at day 21 day and 90.
 ► Montreal Cognitive Assessment (MoCA) score at day 
90.
MEthods And AnAlysIs
study overview
This study is a randomised, multicentre, open-label 
parallel group study to determine the feasibility of 
conducting such a trial in a National Health Service 
(NHS) setting to investigate class effects of antihyperten-
sive medications on BPV in patients with acute ischaemic 
stroke or TIA. The aim is to evaluate barriers to recruit-
ment, identify potential safety issues and demonstrate 
that it is possible to detect differences in BPV over the 
proposed study duration. We also hope to investigate the 
potential therapeutic benefit of targeting BPV after acute 
ischaemic stroke/TIA in terms of functional outcome 
in order to help estimate the necessary sample size for a 
future definitive trial. A summary of the study design is 
provided in figure 1. Recruitment commenced in January 
2018 and is ongoing. The trial was prospectively regis-
tered: International Standard Randomised Controlled 
Trial Number 10853487.
Patient and public involvement
The trial was conceived and designed without the involve-
ment of patients or members of the public.
trial participants
All adult patients with clinically definite first-ever isch-
aemic stroke or TIA within 7 days of onset will be consid-
ered for the trial.
Inclusion criteria
 ► Age >18 years.
 ► Patients with first-ever clinically definite TIA and 
ischaemic stroke (NIHSS <10).
 ► Within 7 days of symptom onset (this criterion was 
initially within 72 hours of symptom onset, but was 
altered with a substantial amendment to the protocol 
to try and improve recruitment).
 ► Casual BP >130/80 mm Hg on repeat measurements.
 ► Ability to comply with randomly assigned BP-lowering 
regime and BP measurements.
 ► Able to understand written and verbal English.
 ► Able to give informed consent.
 ► Willing to allow his or her general practitioner 
(GP) and consultant, if appropriate, to be notified of 
participation in the study.
Exclusion criteria
The participant may not enter the trial if any of the 
following apply:
 ► Known definite contraindication to BP-lowering 
regime or therapeutic agents.
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 ► Swallowing difficulties which would preclude the 
taking of oral medication.
 ► Definite indication for BB, CCB, ACEI or ARB therapy.
 ► Significant prestroke dependency (mRS >3).
 ► Coexisting life-threatening condition with life expec-
tancy <3 months.
 ► Previous participation in this trial or current partici-
pation in another investigational drug trial.
 ► Atrial fibrillation.
 ► Female participants who are pregnant, lactating or 
planning pregnancy during the course of the study.
 ► Unable to understand written and verbal English.
 ► Cannot give informed consent.
Identification of participants
Patients with first-ever TIA and minor ischaemic 
stroke referred to and assessed by the inpatient and/or 
outpatient stroke services at three centres within 7 days of 
symptom onset will be identified by the treating clinician 
and/or the research team. If the patient provides verbal 
consent to be considered for the study then their medical 
records will then be assessed against the study inclusion 
and exclusion criteria. Patients known to be hyperten-
sive and on treatment prior to their cerebrovascular 
event should have their antihypertensive medications 
suspended at admission, in keeping with standard practice 
at the recruiting centres, unless there is a specific indica-
tion for them to continue. Where treatment is suspended 
and the patient is willing to be considered for the trial 
then they are potentially eligible for inclusion provided 
other inclusion/exclusion criteria are not violated. Once 
a potential participant has been confirmed to be eligible 
then research staff will approach the individual to discuss 
the study in more detail, provide a participant informa-
tion sheet and seek written informed consent.
obtaining informed consent
The participant must personally sign and date the latest 
approved version of the informed consent form, counter-
signed by a delegated member of the research team, before 
any study-specific procedures are performed. Written and 
verbal versions of the participant information sheet and 
informed consent form will be presented to the partici-
pants detailing no less than: the exact nature of the study; 
the implications and constraints of the protocol; and the 
known side effects and any risks involved in taking part. It 
will be clearly stated that the participant is free to withdraw 
from the study at any time for any reason without prejudice 
to future care, and with no obligation to give the reason for 
withdrawal. The person who obtained the consent must be 
suitably qualified and experienced, and authorised to do so 
by the chief/principal investigator as detailed on the dele-
gation of authority and signature log for the study. The orig-
inal signed form will be retained at the study site within the 
investigator site file. A copy of the signed informed consent 
will be given to participants and a copy retained in their 
medical notes.
randomisation
After the baseline assessments eligible patients will 
be randomised using a computer-generated protocol, 
in blocks of 4, to a dihydropyridine CCB or ACEI/
Figure 1 Study flow diagram. ABPM, ambulatory BP monitoring; ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BP, 
blood pressure; CCB, calcium channel blocker; mRS, modified Rankin Scale; TIA, transient ischaemic attack.
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ARB-based regime. The study treatment will be dispensed 
at the baseline visit, but treatment will not be commenced 
within 48 hours of the qualifying event in keeping with 
current recommended practice. The actual therapeutic 
agent used will be at the discretion of the treating clini-
cian, but dictated by the class of therapy that the partici-
pant is assigned to. Prescription of the medication will be 
done by the treating clinician and the initial supply will 
be dispensed by the treating hospital or community phar-
macy in accordance with the hospital’s policy for providing 
discharge or outpatient medication. Further supplies will 
be provided by the participant’s GP. Unblinding will not 
be necessary as there is an open-label study design.
Interventions to be measured
Routine clinical data
The following routine clinical information and investiga-
tion results will be obtained from the medical notes and 
by participant interview:
 ► Demographics (including age, sex, ethnicity, height 
and weight, smoking and alcohol habits).
 ► Medical history and family history of cardiovascular 
disease.
 ► Concomitant medications.
 ► NIHSS.
 ► mRS (including premorbid mRS).
 ► Oxford Community Stroke Project and Trial of ORG 
10172 in Acute Stroke Treatment classification.
 ► Laboratory tests (including full blood count, clotting, 
urea, electrolytes, creatinine, estimated glomerular 
filtration rate, total cholesterol and random glucose).
 ► 12-lead ECG (±24 hours ECG if performed).
 ► Imaging investigations (including neuroimaging (CT 
or MRI), carotid ultrasound and cardiac echocardiog-
raphy where applicable).
BP measurements
Baseline casual BP will be calculated as a mean of two sets 
of three supine brachial BP readings taken 10 min apart 
using a UA767 BP monitor (referred to as enhanced 
casual BP).
Three consecutive periods of 10 min beat-to-beat 
non-invasive BP monitoring in the supine position using 
the middle finger of the non-hemiparetic hand will be 
recorded with a Finometer device. The servo adjust mech-
anism of the Finometer will be switched off during the 
recording period, but applied at 10 min intervals during 
the monitoring period.
Daytime ambulatory BP monitoring (ABPM) will 
be performed using a SpaceLabs 90207 monitor, 
programmed to measure BP at 20 min intervals. Daytime 
is defined as between 07:00 and 22:00 hours.
Cognitive testing
A battery of cognitive tests will be performed. This will 
include the MoCA screening test which is established 
for use after cerebrovascular events, augmented with 
the Albert’s line test for inattention, the Motor Neuron 
Disease Behavioural Instrument for frontal cognitive 
symptoms and the Geriatric Depression Scale to exclude 
significant concurrent anxiety/depression.
Follow-up assessments
These will be undertaken at day 21 (±7 days) and day 90 
(±14 days) in the trial centre or where the patient is resi-
dent at the time (including the hospital ward, rehabilitation 
facility or their own home). Interventions that will repeated 
at these follow-up visits are summarised in table 1. Additional 
follow-up interventions to assess the trial feasibility and 
safety will include assessment of treatment compliance using 
a self-reported questionnaire and tablet count (with compli-
ance defined as ≥80%), and assessment of any side effects 
and SAEs. Patients randomised to the ACEI/ARB arm will 
have repeat renal function blood tests at the first follow-up 
visit in line with standard practice to ensure their safety. In 
Table 1 Summary of trial procedures
Procedures
Visits
Screening Baseline
21 
(±7) 
days
90 
(±14) 
days
Informed consent X
Demographics X
Medical history X
Concomitant medications X X X
ECG X
Clinical investigation results 
(bloods tests, CT/MRI scan 
results)
X
Eligibility assessment X
Randomisation X
Dispensing of study drugs X
Treatment compliance X X
Blood test for renal function 
in ACEI/ARB group
X
NIHSS X X X
mRS X* X X
MoCA X X
Albert’s line test X X
MiND-B X X
GDS X X
Enhanced casual BP X X X
Beat-to-beat BP 
measurements
X X X
Daytime ABPM X X
SAEs X X†
*Including premorbid mRS.
†SAEs at day 90 followed up until resolution.
ABPM, ambulatory BP monitoring; ACEI, ACE inhibitor; ARB, 
angiotensin receptor blocker; BP, blood pressure; GDS, Geriatric 
Depression Scale; MiND-B, Motor Neuron Disease Behavioural 
Instrument; MoCA, Montreal Cognitive Assessment; mRS, 
modified Rankin Scale; NIHSS, National Institutes of Health Stroke 
Scale; SAE, serious adverse event. 
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those patients failing to reach casual supine/sitting BP target 
of <130/80 mm Hg, the medical assessor at the follow-up 
visit will advise about altering BP-lowering treatment and 
this will be communicated to the participant’s GP. The first-
line change will be to increase the study regime medication 
(ie, CCB or ACEI/ARB) to twice the starting dose. If the 
patient is on the maximum dose of the study regime medi-
cation already, then the second-line change will be to add a 
thiazide-like diuretic. If a third-line change is required then 
spironolactone or an alpha-blocker will be added to the 
combination of study medication and thiazide-like diuretic. 
After the second follow-up visit ongoing management of the 
patient's BP will be taken over by the GP.
outcome measurements
Primary feasibility outcome measure
Recruitment and retention rates at 3 months from the 
screening and management logs, and reasons for ineligi-
bility or non-inclusion of those screened but not recruited.
Secondary feasibility outcome measures
A. Changes in BPV from baseline to 21 (±7) days and 90 
(±14) days by treatment arm.
B. Proportions of participants achieving ≥80% treatment 
compliance by treatment arm.
C. Treatment discontinuation rates.
D. Completion and failure rates of BPV measurements at 
21 (±7) days and 90 (±14) days.
E. SAE rates by treatment arm.
Exploratory outcome measures
A. mRS at 90 (±14) days by treatment arm.
B. mRS at 21 (±7) days by treatment arm.
C. NIHSS at 21 (±7) days by treatment arm.
D. Differences in mean BP at 21 (±7) days and 90 (±14) 
days by treatment arm.
E. Differences in BPV at 21 (±7) days and 90 (±14) days 
by treatment arm.
F. Differences in MoCA score at 90 (±14) days by treat-
ment arm.
sample size calculation
A feasibility study of 150 patients (64 patients per group 
with a 15% dropout rate) will have an 80% power at 
the 5% significance level of detecting an 8 mm Hg 
difference in systolic BPV between the CCB and ACEI/
ARB-based regimes, assuming a mean systolic BPV SD of 
14.97 mm Hg in the CCB arm and 16.95 mm Hg in the 
ACEI/ARB arm.37
data analysis plan
The primary objective is assessment of feasibility. This will 
focus on recruitment and retention rates, compliance, 
change in BPV and safety of the intervention. Exploratory 
analysis of the effect of the proposed intervention on BPV 
and stroke outcome will be done as a secondary objective.
Recruitment and retention
The total numbers of patients screened, the proportion 
recruited and the proportion completing follow-up will 
be determined. Reasons for ineligibility, non-inclusion 
and withdrawal will be analysed using descriptive statis-
tical methods.
Assessment of the intervention
Compliance with the intervention will be assessed by the 
proportion of participants who achieve ≥80% adherence 
to the trial medication and the proportion of participants 
who have all BP measurements recorded successfully.
The feasibility of detecting changes in BPV will also be 
assessed. Within-individual systolic, diastolic and mean 
BPV will be expressed as the SD, coefficient of variation, 
average real variability and variation independent of the 
mean calculated from all BP measurements: enhanced 
casual, beat-to-beat measurements (each 10 min 
recording and the total 30 min recording), and daytime 
ABPM.42 Changes in within-individual BPV from base-
line to the follow-up time points will be analysed using a 
general linear model. The size of the mean difference will 
be estimated for each approach and compared to select 
the most appropriate measure for a future study.
Safety
Rates of SAEs, including recurrent stroke/TIA, other 
cardiovascular events, death and hospitalisation, will 
be recorded up to 3 months. A descriptive comparison 
will be undertaken to compare the rates, but no formal 
hypothesis testing will be undertaken.
Exploratory analyses
Mean BP will be calculated from enhanced casual 
measurements. Change in mean BP from baseline to 
follow-up by treatment arm will be compared using an 
independent samples t-test.
An assessment of treatment effect on BPV will be 
undertaken stratified according to treatment arm. A 
general linear model will be used with BPV as the depen-
dent variable and treatment arm as the independent vari-
able, adjusting for baseline BP and diagnosis (stroke vs 
TIA). Each expression of BPV as described above will be 
analysed.
Exploratory assessment of treatment effect on stroke 
outcome will be undertaken by comparing between-
group differences in mRS and MoCA score at follow-up 
using independent samples t-tests or a non-parametric 
test if the assumptions of the t-test are violated.
Ethics and dissemination
This study was granted ethical approval in England 
(London–Central Research Ethics Committee, REC 
17/LO/1427) and clinical trial authorisation from the 
Medicines and Healthcare products Regulatory Agency 
(EudraCT number 2017-002560-41). Subsequently, the 
trial was approved by the Health Research Authority. 
Study oversight will be conducted through regular meet-
ings of a Trial Steering Committee and a separate Safety 
Committee, both of which will include independent 
representatives. If it is felt that the risk to participants 
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is significant or unacceptable the Safety Committee can 
recommend early termination of the trial.
The proposed investigational medicinal products are 
antihypertensives that are already in routine use and 
so their safety profiles are known. The medications are 
expected to lower the BP of participants. Therefore, in 
line with accepted stroke guidelines we will only recruit 
patients with uncontrolled BP (>130/80 mm Hg) who 
would otherwise require antihypertensive treatment for 
secondary stroke prevention. Medications that inhibit 
the renin-angiotensin system are known to potentially 
cause kidney dysfunction in patients with unrecognised 
renal artery stenosis. To ensure the safety of patients 
commenced on these medications a blood test for kidney 
function will be done at the 2–4 weeks follow-up which is 
in keeping with standard practice.
The trial will be conducted in accordance with the 
Declaration of Helsinki and the ICH Guidelines for Good 
Clinical Practice. All participants will provide written 
informed consent. Data will be collected and handled 
in line with sponsor standard operating procedures and 
NHS Trust policies. Electronic data will be anonymised 
and all data will be kept under secure conditions. TGR 
will act as data custodian.
Dissemination of the study results is planned via publi-
cation in peer-reviewed medical journals and presenta-
tion at relevant scientific conferences. Any reporting will 
adhere to the Consolidated Standards of Reporting Trials 
statement extension for pilot and feasibility trials. We do 
not intend to employ professional writers.
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